Dr. Goldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
VCU Department of Neurology
Richmond, VA 23298Phone+1 804-827-1504
Education & Training
Rush University Medical CenterInternship, Internal Medicine, 1999 - 2000
Rush Medical College of Rush University Medical CenterClass of 1999
Certifications & Licensure
VA State Medical License 2000 - 2026
OH State Medical License 2003 - 2007
IL State Medical License 1999 - 2000- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Clinical Trials
- Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Start of enrollment: 2013 Nov 01
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
- Clinical Importance of Glucose Regulation in Relapsing MS Start of enrollment: 2016 Oct 01
Publications & Presentations
PubMed
- 27 citationsQuantifying six-minute walk induced gait deterioration with inertial sensors in multiple sclerosis subjectsMatthew M. Engelhard, Sriram Raju Dandu, Stephen D. Patek, John Lach, Myla D. Goldman
Gait & Posture. 2016-09-01 - 91 citationsThe EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.Diego Cadavid, Jeffrey A. Cohen, Mark S. Freedman, Myla D. Goldman, Hans-Peter Hartung
Multiple Sclerosis. 2017-01-01 - 16 citationsVitamin D status and age of onset of demyelinating disease.J. Nicholas Brenton, Scott Koenig, Myla D. Goldman
Multiple Sclerosis and Related Disorders. 2014-11-01
Journal Articles
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple SclerosisMyla D Goldman, Amit Bar-Or, JAMA Neurology
Authored Content
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients with Relapsing-Remitting Multiple SclerosisAugust 2020
Press Mentions
The Multiple Sclerosis Clinic(s) and Research at UVAApril 4th, 2018
Multiple Sclerosis: Smoking After Diagnosis Linked to Disease ProgressionSeptember 9th, 2015
Quitting Smoking After MS Diagnosis May Delay Disease ProgressionSeptember 8th, 2015- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
